Login to Your Account



Mundipharma to Co-Develop

Allos Inks Ex-U.S. Folotyn Deal; $50M Up Front for PTCL Drug

By Jennifer Boggs


Wednesday, May 11, 2011
Allos Therapeutics Inc. picked up $50 million in up-front cash in a much-anticipated ex-U.S. deal for peripheral T-cell lymphoma (PTCL) drug Folotyn (pralatrexate) and hopes the co-development and commercialization muscle of Mundipharma International Corp. Ltd. will help Folotyn capture a large portion of second-line PTCL market outside the U.S., estimated at about $400 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription